FES anticorps

N° du produit ABIN931483

Détail du produit anti-FES anticorps

Antigène: FES (Feline Sarcoma Oncogene (FES))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FES est non-conjugé

Application: Western Blotting (WB), ELISA

Immunogène: FES antibody was raised in Mouse using a purified recombinant fragment of FES expressed in E. coli as the immunogen.

Clone: 5A11G5

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1:10,000, WB: 1:500-1:2000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: Supplied as a liquid in ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term storage. Store at -20 °C for long term storage.

Détails sur FES

Antigène: FES (Feline Sarcoma Oncogene (FES))

Autre désignation: FES (FES Produits)

Synonymes: anticorps FPS, anticorps RGD1564385, anticorps AI586313, anticorps BB137047, anticorps c-fes, anticorps FES, anticorps c-fps, anticorps FES proto-oncogene, tyrosine kinase, anticorps feline sarcoma oncogene, anticorps FES, anticorps Fes, anticorps fes

Sujet: FES is the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis. Synonyms: Monoclonal FES antibody, Anti-FES antibody, Feline Sarcoma Oncogene antibody, FPS antibody.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2